Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alkermes plc

Capitalization 4.61B 4B 3.61B 3.45B 6.27B 425B 6.49B 43B 17.07B 203B 17.29B 16.92B 733B P/E ratio 2026 *
-41.4x
P/E ratio 2027 * 37.2x
Enterprise value 5.65B 4.9B 4.43B 4.23B 7.69B 521B 7.96B 52.72B 20.93B 249B 21.19B 20.74B 899B EV / Sales 2026 *
3.15x
EV / Sales 2027 * 2.89x
Free-Float
90.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.47%
1 week-2.50%
Current month-8.17%
1 month-16.97%
3 months-3.02%
6 months+2.48%
Current year-1.22%
1 week 27.03
Extreme 27.03
28.89
1 month 27.03
Extreme 27.03
33.88
Current year 27.03
Extreme 27.03
35.34
1 year 25.16
Extreme 25.165
36.32
3 years 22.01
Extreme 22.01
36.45
5 years 18.43
Extreme 18.43
36.45
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer - 01/01/2005
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Change 5d. change 1-year change 3-years change Capi.($)
-0.47%-2.50%-17.27%+3.87% 4.63B
-1.04%-5.85%-10.14%-9.27% 44.08B
-4.55%-2.61%+14.19%+31.94% 33.16B
-1.44%-2.60%+14.63%+45.41% 30.96B
-5.04%-8.72%-12.13%-17.40% 28.8B
-4.54%-4.59%+142.53%+357.95% 19.74B
+0.66%-3.51%+52.36%+115.62% 13.96B
-7.09%-5.44%+36.61%+153.01% 13.56B
-2.41%-6.09%+23.22%-2.78% 12.88B
-3.28%-3.75%+116.52%+113.02% 12.35B
Average -2.92%-4.71%+36.05%+79.14% 21.41B
Weighted average by Cap. -2.97%-5.06%+27.21%+63.92%

Financials

2026 *2027 *
Net sales 1.8B 1.56B 1.41B 1.34B 2.45B 166B 2.53B 16.76B 6.65B 79.19B 6.74B 6.59B 286B 1.88B 1.63B 1.47B 1.41B 2.56B 173B 2.65B 17.52B 6.96B 82.78B 7.04B 6.89B 299B
Net income -112M -97.43M -88.09M -84.11M -153M -10.37B -158M -1.05B -416M -4.95B -421M -412M -17.88B 138M 120M 109M 104M 189M 12.78B 195M 1.29B 513M 6.11B 520M 508M 22.04B
Net Debt 1.04B 903M 817M 780M 1.42B 96.12B 1.47B 9.72B 3.86B 45.93B 3.91B 3.82B 166B 822M 713M 645M 615M 1.12B 75.87B 1.16B 7.67B 3.05B 36.25B 3.08B 3.02B 131B
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
2,050
Date Price Change Volume
12/03/26 27.64 $ -0.47% 2,597,551
11/03/26 27.77 $ +0.11% 1,638,310
10/03/26 27.74 $ -2.50% 2,471,531
09/03/26 28.45 $ -0.63% 2,027,184
06/03/26 28.63 $ +0.99% 1,924,526
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
27.64USD
Average target price
43.65USD
Spread / Average Target
+57.91%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW